Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised open-label controlled trial of a 4-month gatifloxacin-containing regimen versus standard regimen for the treatment of adult patients with pulmonary tuberculosis

Next Previous
X
Search
Trial Profile

A randomised open-label controlled trial of a 4-month gatifloxacin-containing regimen versus standard regimen for the treatment of adult patients with pulmonary tuberculosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gatifloxacin (Primary) ; Isoniazid/rifampicin; Rifampicin/isoniazid/pyrazinamide; Rifampicin/isoniazid/pyrazinamide/ethambutol
  • Indications Pulmonary tuberculosis
  • Focus Registrational; Therapeutic Use
  • Acronyms OFLOTUB

    • Most Recent Events

    • 22 Feb 2023 Results(n=711) of pooled analysis from four Phase 3 clinical trials (OFLOTUB NCT00216385, REMoxTB NCT00864383, RIFAQUIN ISRCTN44153044, S31/A5349 NCT02410772) assessing Tb Outcomes in People Living with Hiv presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
    • 19 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top